milvexian
bms,janssen
['factor xi', 'axiomatic', 'milvexian']
late-breaking results from phase 2 axiomatic-ssp study of milvexian, an investigational oral factor xia inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy - neuro central via brainsights for ios 
Stay on top of the latest Brain & Neuroscience research & news from all the best sources delivered directly to your iPhone/iPad